Patent details

LUC00179 Product Name: céfidérocol, éventuellement sous la forme d'un sel ou d'un solvate pharmaceutiquement acceptable

Basic Information

Publication number:
LUC00179
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP151750841
Legal Status:
Inactive
Application number:
LUC00179
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1434
Marketing Authorization Type:
Marketing Authorization Date:
24/04/2020
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
13/10/2020
First Marketing Authorization date:
24/04/2020
Grant date:
14/12/2021
Activation date:
Publication date:
13/10/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
27/10/2034
SPC Extension Expiration:
27/10/2034
Rejection date:
Withdrawal date:

Owner

From:
13/10/2020
 
 

Name:
Shionogi & Co. Ltd.
Address:
1-8, Doshomachi 3-chome Chuo-ku Osaka-shi, Osaka 541-0045, Japan (JP)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
13/10/2020
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2020/12
Publication date:
02/11/2020
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2022/01
Publication date:
03/01/2022
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/10/2029
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
13/10/2020 Summary of the product caracteristics 28
13/10/2020 Application Form 4
13/10/2020 MA publication 12
13/10/2020 Marketing authorization 3
13/10/2020 Outgoing Correspondence 1
13/10/2020 Publication 1
14/12/2021 Publication 1
14/12/2021 Certificate 1
14/12/2021 Outgoing Correspondence 1